Kopp Investment Advisors LLC cut its holdings in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 7.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,668 shares of the medical device company’s stock after selling 7,918 shares during the period. NxStage Medical comprises approximately 2.4% of Kopp Investment Advisors LLC’s holdings, making the stock its 15th largest holding. Kopp Investment Advisors LLC owned approximately 0.15% of NxStage Medical worth $2,391,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NXTM. Alpine Associates Management Inc. bought a new stake in NxStage Medical during the 3rd quarter worth approximately $110,163,000. Magnetar Financial LLC bought a new stake in NxStage Medical during the 3rd quarter worth approximately $84,927,000. JPMorgan Chase & Co. grew its position in NxStage Medical by 239,738.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock worth $51,502,000 after acquiring an additional 1,869,961 shares during the last quarter. State of Wisconsin Investment Board grew its position in NxStage Medical by 117.6% during the 4th quarter. State of Wisconsin Investment Board now owns 1,056,447 shares of the medical device company’s stock worth $25,598,000 after acquiring an additional 570,847 shares during the last quarter. Finally, Cheyne Capital Management UK LLP acquired a new position in NxStage Medical during the 3rd quarter worth $524,000. Institutional investors and hedge funds own 84.26% of the company’s stock.
NxStage Medical, Inc. (NASDAQ:NXTM) opened at $24.37 on Monday. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.
In other news, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $24.88, for a total value of $87,080.00. Following the transaction, the senior vice president now owns 13,770 shares of the company’s stock, valued at approximately $342,597.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 10,500 shares of company stock worth $261,485. Company insiders own 4.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “NxStage Medical, Inc. (NXTM) Shares Sold by Kopp Investment Advisors LLC” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/12/nxstage-medical-inc-nxtm-shares-sold-by-kopp-investment-advisors-llc.html.
NxStage Medical Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.